Buy IBRX by May 25, 2025.

Alright, listen up degenerates. If you’ve been sleeping on ImmunityBio ($IBRX), now’s the time to wake the fuck up. This isn’t your average pump-and-dump biotech—these guys just got FDA approval for ANKTIVA, an absolute game-changer in the fight against bladder cancer. Translation? Real revenue incoming. The stock is chilling at around $3.41, which is criminally undervalued considering they’re sitting on a multi-billion-dollar TAM (total addressable market). Oh, and they’ve got marketing applications pending in the UK and EU—when those approvals …